Nieves Fernández-Gallego

Nieves Fernández-Gallego

Auto-generated profile, based on publicly available information

Nieves Fernández-Gallego

Universidad Autónoma de Madrid, Madrid, Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2021 in Cells
Verified
Journal Article
Open access
PDF file
NFNieves Fernández-Gallego
Nieves Fernández-Gallego
FSFrancisco Sánchez-Madrid
Francisco Sánchez-Madrid
DCDanay Cibrian
Danay Cibrian
Aryl hydrocarbon receptor (AHR) is an important regulator of skin barrier function. It also controls immune-mediated skin responses. The AHR modulates various physiological functions by acting as a sensor that mediates environment–cell interactions, particularly during immune and inflammatory responses. Diverse experimental systems have been used to assess the AHR’s role in skin inflammation, including in vitro assays of keratinocyte stimulation and murine models of psoriasis and atopic dermatitis. Similar approaches have addressed the role of AHR ligands, e.g., TCDD, FICZ, and microbiota-derived metabolites, in skin homeostasis and pathology. Tapinarof is a novel AHR-modulating agent that inhibits skin inflammation and enhances skin barrier function. The topical application of tapinarof is being evaluated in clinical trials to treat psoriasis and atopic dermatitis. In the present review, we summarize the effects of natural and synthetic AHR ligands in keratinocytes and inflammatory cells, and their relevance in normal skin homeostasis and cutaneous inflammatory diseases.

18 July 2022 in Allergy
Verified
Journal Article
Closed access
NFNieves Fernández‐Gallego
Nieves Fernández‐Gallego
RCRaquel Castillo‐González
Raquel Castillo‐González
NMNerea Mendez-Barbero
Nerea Mendez-Barbero
CLCelia López‐Sanz
Celia López‐Sanz
DODavid Obeso
David Obeso
RJRODRIGO JIMENEZ-SAIZ
RODRIGO JIMENEZ-SAIZ

12 June 2024 in Allergy
Verified
Journal Article
Open access
NFNieves Fernández‐Gallego
Nieves Fernández‐Gallego
RCRaquel Castillo‐González
Raquel Castillo‐González
LMLucía Moreno‐Serna
Lucía Moreno‐Serna
AGAntonio J. García‐Cívico
Antonio J. García‐Cívico
ESElisa Sánchez‐Martínez
Elisa Sánchez‐Martínez
RJRODRIGO JIMENEZ-SAIZ
RODRIGO JIMENEZ-SAIZ
Background: Allergic diseases begin early in life and are often chronic, thus creating an inflammatory environment that may precede or exacerbate other pathologies. In this regard, allergy has been associated to metabolic disorders and with a higher risk of cardiovascular disease, but the underlying mechanisms remain incompletely understood. Methods: We used a murine model of allergy and atherosclerosis, different diets and sensitization methods, and cell‐depleting strategies to ascertain the contribution of acute and late phase inflammation to dyslipidemia. Untargeted lipidomic analyses were applied to define the lipid fingerprint of allergic inflammation at different phases of allergic pathology. Expression of genes related to lipid metabolism was assessed in liver and adipose tissue at different times post‐allergen challenge. Also, changes in serum triglycerides (TGs) were evaluated in a group of 59 patients ≥14 days after the onset of an allergic reaction. Results: We found that allergic inflammation induces a unique lipid signature that is characterized by increased serum TGs and changes in the expression of genes related to lipid metabolism in liver and adipose tissue. Alterations in blood TGs following an allergic reaction are independent of T‐cell‐driven late phase inflammation. On the contrary, the IgG‐mediated alternative pathway of anaphylaxis is sufficient to induce a TG increase and a unique lipid profile. Lastly, we demonstrated an increase in serum TGs in 59 patients after undergoing an allergic reaction. Conclusion: Overall, this study reveals that IgG‐mediated allergic inflammation regulates lipid metabolism.

1 June 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
RCRaquel Castillo-González
Raquel Castillo-González
DCDanay Cibrian
Danay Cibrian
NFNieves Fernández-Gallego
Nieves Fernández-Gallego
MRMarta Ramírez-Huesca
Marta Ramírez-Huesca
MAMaria Laura Saiz Alvarez
Maria Laura Saiz Alvarez
FSFrancisco Sánchez-Madrid
Francisco Sánchez-Madrid
Allergic contact dermatitis, also known as contact hypersensitivity, is a frequent T-cell‒mediated inflammatory skin disease characterized by red, itchy, swollen, and cracked skin. It is caused by the direct contact with an allergen and/or irritant hapten. Galectin-1 (Gal-1) is a β-galactoside‒binding lectin, which is highly expressed in several types of immune cells. The role of endogenous Gal-1 in contact hypersensitivity is not known. We found that Gal-1‒deficient mice display more sustained and prolonged skin inflammation than wild-type mice after oxazolone treatment. Gal-1‒deficient mice have increased CD8+ T cells and neutrophilic infiltration in the skin. After the sensitization phase, Gal-1‒depleted mice showed an increased frequency of central memory CD8+ T cells and IFN-γ secretion by CD8+ T cells. The absence of Gal-1 does not affect the migration of transferred CD4+ and CD8+ T cells from the blood to the lymph nodes or to the skin. The depletion of CD4+ T lymphocytes as well as adoptive transfer experiments demonstrated that endogenous expression of Gal-1 on CD8+ T lymphocytes exerts a major role in the control of contact hypersensitivity model. These data underscore the protective role of endogenous Gal-1 in CD8+ but not CD4+ T cells in the development of allergic contact dermatitis.

16 June 2023 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
AGAmelia Rojas Gomez
Amelia Rojas Gomez
SDSara G. Dosil
Sara G. Dosil
FCFrancisco J. Chichón
Francisco J. Chichón
NFNieves Fernández‐Gallego
Nieves Fernández‐Gallego
AFAlessia Ferrarini
Alessia Ferrarini
NMNoa B Martin-Cofreces
Noa B Martin-Cofreces
SUMMARY: CCT is required to regulate interorganelle contact sites through kinesin‐1 dynamics, modulating peroxisome and mitochondria activity, and ultimately controlling lipid cell content and metabolism.

24 October 2025 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
PDF file
PMPedro Martínez-Fleta
Pedro Martínez-Fleta
CPClara Pertusa
Clara Pertusa
Irene Fernández DelgadoIrene Fernández Delgado
Irene Fernández Delgado
RIRaúl Izquierdo-Serrano
Raúl Izquierdo-Serrano
MRMarta Ramírez-Huesca
Marta Ramírez-Huesca
FSFrancisco Sánchez-Madrid
Francisco Sánchez-Madrid
The Interferon-Stimulated Gene 15 (ISG15) has a key role during viral infections, since it can modify and regulate the expression of proteins from the host and from viruses. Isg15 −/− mice are more susceptible to infectious diseases. ISG15 is induced by type I Interferons (IFN-I) and apart from defense against pathogens, it can also play an important function in cancer or immune-mediated inflammatory diseases. Previous studies reported that ISG15 expression is increased in post-synaptic dendritic cells (DCs) upon interaction with CD4 + T cells. However, data regarding the role of ISG15 in DCs are scarce. The present study assesses the function of ISG15 in DCs activation, migration and ability to mediate T cell activation using bone marrow-derived DCs (BMDCs) and stimulation with lipopolysaccharide (LPS). Activation of DCs was not impaired but tended to be lower in Isg15 -deficient mice, as observed by reduced CD40 induction in Isg15 −/− BMDCs. Isg15 −/− BMDCs induced less proliferation and Granzyme B expression in co-cultured CD8 + T cells. Interestingly, Isg15 −/− BMDCs secreted reduced levels of the pro-inflammatory cytokines IL-1β and IL-12 upon LPS stimulation. Mechanistically, our data suggest that ISG15 regulates Caspase-1 activity in DCs leading to lower IL-1 β secretion. In conclusion, this study reveals an essential role for ISG15 modulating DCs inflammatory activity and raises new questions regarding the specific mechanisms of how this protein regulates innate immune responses.